Functional class and comorbidity drive health status in ambulatory older adults with

heart failure

Nguyen Le Huy Hoang[1*], Pham Thi Ngoc Anh[1], Trinh Cong Tuan[1], Than Ha Ngoc The[1,2],

Nguyen Ngoc Hoanh My Tien[1,2], and Pham Huy Tung[3]

Work performed at Thong Nhat Hospital, Ho Chi Minh City, Vietnam.

[1]School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi

Minh City, Vietnam.

[2]Department of Geriatrics and Palliative Care, University Medical Centre Ho Chi Minh City,

Ho Chi Minh City, Vietnam.

[3]Department of Radiology, Thong Nhat Hospital, Ho Chi Minh City, Vietnam.

*Corresponding author:

Nguyen Le Huy Hoang, MD, MSc

Position: cardiologist and geriatrician

Institution: School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City

Address: 217 Hong Bang Street, Cho Lon Ward, Ho Chi Minh City, Vietnam

Phone number: +84 946 639 943

Fax: not available

Email: lucian.nguyen@icloud.com

ORCID ID: 0009-0002-2791-2838

Other authors:

Pham Thi Ngoc Anh, MD, MSc

Position: physician

Institution: School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City

Address: 217 Hong Bang Street, Cho Lon Ward, Ho Chi Minh City, Vietnam

Email: phamthingocanh798@gmail.com

Trinh Cong Tuan, MD, MSc

Position: physician

Institution: School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City

Address: 217 Hong Bang Street, Cho Lon Ward, Ho Chi Minh City, Vietnam

Email: tringcongtuan@gmail.com

Than Ha Ngoc The, MD, PhD

Position: lecturer and physician

Institution: School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City

and Department of Geriatrics and Palliative Care, University Medical Centre Ho Chi Minh

City

Address: 217 Hong Bang Street, Cho Lon Ward, Ho Chi Minh City, Vietnam

Email: the.thn@umc.edu.vn

Nguyen Ngoc Hoanh My Tien, MD, MSc, Specialist Level 2

Position: lecturer and physician

Institution: School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City

and Department of Geriatrics and Palliative Care, University Medical Centre Ho Chi Minh

City

Address: 217 Hong Bang Street, Cho Lon Ward, Ho Chi Minh City, Vietnam

Email: tien.nnhm@umc.edu.vn

Pham Huy Tung, MD, MSc

Position: radiologist

Institution: Department of Radiology, Thong Nhat Hospital

Address: 1 Ly Thuong Kiet Street, Tan Son Nhat Ward, Ho Chi Minh City, Vietnam

Email: tunghuy516@gmail.com

Total word count: 2,969 words

Abstract

Aims

Heart failure (HF) management in older adults is complicated by cardiac decline,

comorbidities and frailty. Current practice categorises patients by left ventricular ejection

fraction (LVEF) into heart failure with reduced ejection fraction (HFrEF), mildly reduced

ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF). However, LVEF

frequently shows weak relationships with patient symptoms and functional limitations. We

examined associations among patient-reported health status as measured by the Kansas City

Cardiomyopathy Questionnaire-12 (KCCQ-12), New York Heart Association (NYHA)

functional classes and comorbidity burdens across HF phenotypes.

Methods

This cross-sectional study included 150 older patients (median age: 75 years) with chronic

HF recruited from a tertiary centre in Vietnam between August 2024 and March 2025. The

patients were categorised by LVEF as HFrEF (n = 54), HFmrEF (n = 23) or HFpEF (n = 73).

We assessed KCCQ-12 scores; NYHA class; frailty, using the Clinical Frailty Scale; and

comorbidity burden, using the Charlson Comorbidity Index (CCI). Multivariable linear

regression identified independent predictors of KCCQ-12 scores, adjusting for age, sex,

NYHA class, CCI, heart rate, N-terminal pro-B-type natriuretic peptide (NT-proBNP),

smoking status, sodium-glucose cotransporter-2 inhibitor (SGLT2i) use and HF phenotype.

Results

HF disease burdens were similar across phenotypes, with no significant differences in median

KCCQ-12 scores (HFrEF: 70.3; HFmrEF: 72.4; HFpEF: 66.1; $p = 0.494$), NYHA class

distribution ($p = 0.138$) or frailty rates ($p = 0.243$). Multivariable analysis revealed that higher

comorbidity burdens (CCI: β coefficient -2.36, 95% confidence interval [CI] -3.03 to -1.69; p

< 0.001) and worse NYHA class (Class III vs. I: β -25.74, 95% CI -29.33 to -22.16; $p < 0.001$)

strongly predicted lower KCCQ-12 scores, whilst LVEF-based phenotypes did not (HFmrEF

vs. HFrEF: β −1.35, p = 0.465; HFpEF vs. HFrEF: β 0.86, p = 0.550). SGLT2i use was

independently associated with 3.89-point higher KCCQ-12 scores (95% CI 1.30 to 6.48; p =

0.003). The model explained 85% of the variance in health status ($R^2 = 0.851$).

Conclusions

In older adults with HF, patient-reported disease burdens were similar across LVEF-based

phenotypes and more strongly associated with functional limitations and comorbidities.

These findings support patient-centred approaches prioritising comprehensive assessments of

functional capacity and comorbidity burdens over LVEF-based classification in geriatric HF

management.

Keywords: Heart failure, quality of life, frailty, patient-reported outcomes, left ventricular

ejection fraction, geriatric

Introduction

Heart failure (HF) is a worldwide health crisis with a growing prevalence, largely due

to an ageing global population, and is a leading cause of death and illness that significantly

diminishes patients' health-related quality of life (HRQoL).[1] Among older patients, HF

frequently coexists with multiple other medical conditions and geriatric syndromes such as

frailty, creating a complex clinical picture in which treatment goals must centre on patient-

centred outcomes such as physical function and overall well-being.[2] Consequently, current

clinical practice guidelines strongly recommend the regular measurement of patient-reported

outcomes (PROs) to capture the full impact of this disease beyond standard physiological

metrics.[3]

The fundamental approach to diagnosing and treating HF relies on categorising

patients into three groups based on left ventricular ejection fraction (LVEF): HF with reduced

ejection fraction (HFrEF; LVEF ≤ 40%), HF with mildly reduced ejection fraction (HFmrEF;

LVEF 41–49%), and HF with preserved ejection fraction (HFpEF; LVEF ≥ 50%).[4] This

classification system is the cornerstone for determining evidence-based treatment, with

specific pharmacological and device therapies tailored to each category.[5] However, despite its

central role in guiding therapy, LVEF often correlates weakly with patients' actual symptom

burden, functional limitations, and self-reported quality of life, highlighting a disconnect

between this cardiac measure and the patient experience.[6] To measure the patient's

perspective, the Kansas City Cardiomyopathy Questionnaire (KCCQ) has emerged as the

most widely used and scientifically validated PRO instrument.[7] The short-form KCCQ-12,

which was used in this study, has well-established psychometric properties,[8] and recent large-

scale studies have confirmed that KCCQ scores provide powerful prognostic information

independent of traditional clinical markers.[9]

Although the three HF phenotypes are distinct, researchers have long debated whether

patients experience a significantly different disease burden across the LVEF spectrum.

Foundational studies show that KCCQ scores are comparable in patients with both reduced

and preserved ejection fraction.[10] Therefore, substantial uncertainty remains about whether

LVEF-based classification or other clinical factors best predict patient-reported health status.

Growing evidence suggests that factors unrelated to LVEF, such as physician-assessed

functional limitation (New York Heart Association [NYHA] functional class) and the

cumulative burden of coexisting diseases, may better predict HRQoL, particularly in the

medically complex population of HF patients.[11]

This study aimed to identify the main factors influencing patient-reported health

status in a group of older outpatients with chronic HF receiving regular care. More

specifically, we examined the relationships between health status as measured by the KCCQ-

12 questionnaire, NYHA functional class categories, and the burden of multiple medical

conditions across the three HF phenotypes. We hypothesised that among older adults,

measures of functional capacity and multimorbidity would show stronger associations with

patient-perceived disease burdens than the LVEF-based classification system, and that these

measures would thus support a more patient-centred framework for evaluation and treatment

planning.

Methods

Study population and design

This cross-sectional, single-centre study was conducted at Thong Nhat Hospital, a tertiary

care facility in Ho Chi Minh City, Vietnam. Between August 2024 and March 2025, patients

aged 60 years or older with a clinical diagnosis of chronic HF were recruited from the

outpatient cardiology clinic. Key inclusion criteria were the ability to provide informed

consent and complete study questionnaires. Exclusion criteria included acute decompensated

HF and significant cognitive impairment that would preclude reliable questionnaire

completion. The study protocol was approved by the Institutional Review Board of the

University of Medicine and Pharmacy at Ho Chi Minh City and complied with the principles

of the Declaration of Helsinki and the Belmont Report, as well as Good Clinical Practice. All

participants provided written informed consent. This submission conforms to International

Committee of Medical Journal Editors (ICMJE) recommendations. The patient selection

process is shown in a flow diagram in Figure 1.

Procedures and data collection

Baseline demographic and clinical data were systematically collected from medical

records and patient interviews. All participants underwent a comprehensive evaluation,

including New York Heart Association (NYHA) functional classification by an

experienced cardiologist and quantification of disease-specific health status via the

validated Vietnamese version of the Kansas City Cardiomyopathy Questionnaire

(KCCQ-12). Comorbidities were recorded to calculate the Charlson Comorbidity Index

(CCI).

Clinical definitions and assessments

HF phenotypes were classified based on LVEF according to the 2021 European Society

of Cardiology (ESC) guidelines: an LVEF ≤ 40% was recorded as HFrEF, an LVEF

41–49% was recorded as HFmrEF, and an LVEF ≥ 50% was recorded as HFpEF.[5]

Hypertension was defined by a documented history, the use of antihypertensive

medication, or a recorded blood pressure ≥ 140/90 mmHg. Coronary artery disease

(CAD) was defined by a history of myocardial infarction, coronary revascularisation,

or significant stenosis on angiography. Chronic kidney disease (CKD) was defined as

an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m² for at least three

months. Body mass index (BMI) was classified using the 2004 World Health

Organization (WHO) criteria for Asian populations.[12] Polypharmacy was defined as the

concurrent use of at least five prescribed medications.[13] Frailty was assessed using the

Clinical Frailty Scale (CFS) and defined as a CFS score ≥ 4.[14] Limitations in activities

of daily living (ADL) were defined as a Katz ADL score < 6,[15] and limitations in

instrumental activities of daily living (IADL) were defined as a Lawton IADL score <

8.[16]

Study endpoints

The primary endpoint was patient-reported health status, measured by the KCCQ-12 overall

summary score. KCCQ-12 scores range from 0 to 100, with higher scores indicating better

health statuses.[8] Key secondary endpoints included the distribution of NYHA functional class,

the prevalence of frailty, scores on individual KCCQ-12 domains, and measures of functional

independence across the three HF phenotypes.

Statistical analysis

The sample size was set to estimate the mean KCCQ-12 overall summary score with an

standard deviation (SD) of 25 and a margin of error of 5 at the 95% confidence level,

giving a minimum n = $(Z^2 \times SD^2) / E^2$ with Z = 1.96 and n = 97. The final cohort of

150 exceeded this threshold. Analyses were conducted using standard statistical

software. Multivariable linear regression was estimated by ordinary least squares with

heteroskedasticity-robust (Huber–White/sandwich) standard errors. Model-wide

inference was conducted using robust Wald tests consistent with a heteroskedasticity-

robust variance estimator. Two-tailed p values < 0.05 were considered statistically

significant. Continuous variables were summarised as mean (SD) or median

(interquartile range), and categorical variables as n (%). Across-phenotype comparisons

used Welch's one-way ANOVA, the Kruskal–Wallis H test, or Fisher's exact test, as

appropriate. Post hoc pairwise comparisons used Dunn's test or Fisher's exact tests

with Bonferroni correction. The primary multivariable model included age, sex, NYHA

functional class, Charlson Comorbidity Index, heart rate, log-transformed NT-proBNP,

smoking status, SGLT2 inhibitor use, and HF phenotype. Stratified models were fitted

within each phenotype. A prespecified sensitivity model replaced HF phenotypes and

sodium-glucose cotransporter 2 (SGLT2) inhibitor use with a continuous LVEF

measure and the number of foundational therapies (0–4 drugs), retaining the other

covariates. Model assumptions were assessed using variance inflation factors

(multicollinearity), residual-versus-fitted and scale–location plots (linearity and mean–

variance patterns), and Q–Q plots and the Shapiro–Wilk test (residual normality).

Heteroskedasticity-robust standard errors were applied to ensure valid inference under

variance heterogeneity.

Results

Baseline characteristics of the study cohort

A total of 150 ambulatory patients aged 60 years or older with chronic HF were included in

the final analysis. This study was reported in accordance with the Strengthening the

Reporting of Observational Studies in Epidemiology (STROBE) statement. The patient

screening and selection process is detailed in a flow diagram (Figure 1). The cohort was

stratified into three phenotypes: HFrEF, HFmrEF, and HFpEF. The overall study population

was characterised by advanced age and a high comorbidity burden. The complete baseline

demographic, clinical, and laboratory characteristics of the study population are detailed in

Table 1. The most significant baseline differences observed were that patients with HFpEF

were older and had a higher prevalence of atrial fibrillation compared with those with HFrEF

(Supplementary Table 1). Additionally, baseline treatments and medication burdens differed

across phenotypes, with patients with HFrEF and HFmrEF showing significantly higher use

of mineralocorticoid receptor antagonists and SGLT2 inhibitors compared to those with

HFpEF (MRA $p < 0.001$; SGLT2i $p = 0.004$). Significant differences were also noted in beta-

blocker use ($p = 0.040$) and polypharmacy prevalence ($p = 0.018$; Table 1; Supplementary

Table 1).

Primary endpoint: Patient-reported health status and its independent predictors

The primary analysis revealed no statistically significant difference in patient-reported health

status, as measured by the KCCQ-12 overall summary score, across the three HF phenotypes

(Table 2). A multivariable linear regression analysis was performed to identify independent

predictors of KCCQ-12 scores (Table 3). In the multivariable model, the strongest predictors

of lower KCCQ-12 scores were a higher comorbidity burden (CCI: $\beta = -2.36$, 95%

confidence interval [CI] -3.03 to -1.69; $p < 0.001$) and a higher NYHA functional class (Class

III vs. I: $\beta = -25.74$, 95% CI -29.33 to -22.16; $p < 0.001$). After adjusting for these factors,

LVEF-based phenotypes were not significant predictors of KCCQ-12 scores. In contrast, the

use of SGLT2i was independently associated with a significantly higher KCCQ-12 score (β =

3.89, 95% CI 1.30 to 6.48; p = 0.003).

Secondary endpoints and subgroup analyses

Analyses of secondary endpoints showed no statistically significant differences across the HF

phenotypes in the distribution of NYHA functional classes, the prevalence of frailty, any of

the individual KCCQ-12 domain scores, or in measures of functional independence (Table 2).

Increasing NYHA class was associated with progressively lower KCCQ-12 scores (Figure

2A), and frail patients reported lower health statuses than non☐frail patients, as depicted in

Figure 2B. In stratified multivariable regression analyses, NYHA functional classes and CCI

scores remained significant independent predictors of KCCQ-12 scores within both the

HFrEF and HFpEF subgroups (Table 4). The use of SGLT2i was associated with significantly

higher KCCQ-12 scores within the HFpEF subgroup. In the HFmrEF subgroup, the male sex

(β = -7.71, p = 0.046) and higher LVEF (β = -1.68, p = 0.007) were associated with lower

KCCQ☐12 scores, whereas higher log(NT☐proBNP) (β = 5.33, p = 0.007) and being a

current or former smoker (β = 6.75, p = 0.040) were associated with higher KCCQ☐12 scores;

however, these findings should be interpreted with caution. However, these findings should

be interpreted with caution as the analysis for the HFmrEF subgroup yielded insufficient

evidence to support a definitive conclusion, primarily due to the limited sample size.

Effects of foundational therapy on health status

Among the 54 patients with HFrEF, the majority were prescribed three (37.0%) or four

(29.6%) foundational therapies (Supplementary Table 2). A secondary analysis assessed the

impact of foundational HF therapies on patient-reported health status, revealing a distinct

threshold effect. Compared with no therapy, monotherapy showed no significant

improvement in KCCQ-12 scores (β = 1.84; 95% CI -2.73 to 6.42). However, combination

therapy with two or more agents yielded significant improvements (two drugs, β = 6.20; three

drugs, β = 8.31; and four drugs, β = 7.93). While using three (β = 8.31) and four (β = 7.93)

drugs were both linked to significant improvements, the similar coefficients suggest a plateau

in the benefit gained when increasing from three to four agents (Supplementary Table 3).

Discussion

Summary of key findings

In this cross-sectional study of older adults with chronic HF, patient-reported health status

was markedly dissociated from LVEF-based phenotypes. The primary finding was the

absence of a significant difference in KCCQ-12 scores across HFrEF, HFmrEF, and HFpEF

phenotypes. Multivariable analysis identified higher NYHA functional class and higher

comorbidity burden as the dominant determinants of lower health status, while SGLT2

inhibitor use was associated with higher KCCQ-12 scores. A therapeutic threshold effect was

observed: significant improvements in health status occurred with two or more foundational

therapies.

Interpretation and context of the primary finding: The primacy of function over

fraction

This study's central finding—that older adults experience a uniformly high disease burden

irrespective of their LVEF-based HF classification—challenges the clinical utility of ejection

fraction as a primary surrogate for the patient's lived experience. Our results align with and

extend prior work demonstrating that the KCCQ is a valid and reliable measure of health

status that performs comparably across the LVEF spectrum, making it a suitable phenotype-

agnostic endpoint.[10] Furthermore, the patient-reported data in this study provide a direct

corollary to clinical findings from studies such as Warraich et al., which found that

hospitalised older adults with HFpEF and HFrEF had equally severe impairments in physical

function, frailty, and cognition.[11] The convergence of evidence from both patient-reported

outcomes and clinician-assessed measures of functional limitation (NYHA class) and

comorbidity burden (CCI) strongly supports a unified understanding of geriatric HF. The

observed dissociation between LVEF and symptoms suggests that in older adults, diverse

underlying cardiac pathologies converge on a "final common pathway" of functional decline.

This pathway appears to be driven by a constellation of extra-cardiac factors and geriatric

syndromes, including sarcopenia, CKD, anaemia, endothelial dysfunction, and systemic

inflammation, that are inadequately captured by a single measure of resting ventricular

contractility.[2,17] Holistic measures such as the NYHA classification, which synthesises the

impact of these multisystemic derangements on a patient's exertional capacity, and the CCI,

which quantifies cumulative comorbidity, are thus more robust predictors of health status

than LVEF-based classifications.

Discussion of secondary findings and key subgroup analyses

Two secondary findings from this study also have significant clinical implications. First, the

independent association of SGLT2i use with higher KCCQ-12 scores provides real-world

corroboration for the robust patient-reported outcome data from landmark randomised

controlled trials. In patients with HFrEF, both the DAPA-HF and EMPEROR-Reduced trials

reported significant KCCQ improvements with SGLT2i.[18,19] These benefits were extended

across the full LVEF spectrum in the EMPEROR-Preserved and DELIVER trials, which

demonstrated similar gains in health status for patients with HFmrEF and HFpEF.[20,21] The

consistent pan-EF benefit of this drug class on health status is likely attributable to its

systemic mechanisms of action, including osmotic diuresis, improved renal haemodynamics,

and favourable metabolic and anti-inflammatory effects, which directly address

multisystemic symptom drivers rather than targeting LVEF itself.[22] Second, the novel

observation of a therapeutic threshold, where a significant benefit in KCCQ-12 scores

emerged with the initiation of a second foundational therapy with an apparent plateau

between the third and fourth agents, warrants careful consideration. This finding must be

interpreted within the contexts of polypharmacy and treatment burdens, which are pervasive

in geriatric cardiology.[23] While contemporary guidelines rightly advocate for maximising

guideline-directed medical therapy (GDMT) to improve mortality and morbidity, our data

suggest that for frail, older adults, the cumulative burden of adding a fourth agent—

encompassing the pill burden, cost, and the potential for adverse drug events—may offset its

marginal pharmacological benefit on quality of life.[24] Exploratory subgroup analyses in

HFmrEF suggested that the male sex and higher LVEF were associated with lower KCCQ-12

scores, while higher log(NT☐proBNP) and current or former smoking were associated with

higher scores; these findings require cautious interpretation given their limited statistical

power. Finally, it is imperative to note that the stratified analysis for the HFmrEF subgroup (n

= 23) was severely underpowered. The statistical associations observed within this small

cohort are highly susceptible to Type I error and must be considered hypothesis-generating

only—requiring rigorous validation in larger, dedicated studies of this specific HF population.

Strengths and limitations of the study

The principal strength of this study is its patient-centred design, which utilised a validated,

disease-specific patient-reported outcome measure, the KCCQ-12, as the primary endpoint

within a dedicated geriatric cohort. An additional strength is the comprehensive clinical

characterisation of the population, which included formal assessments of both comorbidity

burden and frailty (CFS), permitting a more holistic analysis of the determinants of health

status. However, several limitations must be acknowledged. The study's cross-sectional

design is the most significant limitation, as it precludes any inference of causality; thus, only

associations can be reported. The single-centre design, conducted at a tertiary care facility in

Vietnam, may limit the generalisability of the findings to other healthcare systems or patient

populations. As previously noted, the small sample size of the HFmrEF subgroup prevents

definitive conclusions regarding this specific phenotype. Furthermore, reliance on self-

reported questionnaire data introduces the potential for recall and social desirability biases.

Finally, the analysis may be subject to unmeasured confounding from factors such as

socioeconomic status, medication adherence, and the availability of social support, all of

which can influence patient-reported outcomes.[24] The findings remained robust in sensitivity

analyses using alternative model specifications, including substitution of the number of

foundational therapies for individual medication classes (Supplementary Table 3), which

supported the validity of our primary conclusions.

Clinical implications and future directions

The primary clinical implication is the need for a paradigm shift in the routine assessment of

older HF patients. Evaluation should prioritise and formally document functional status,

frailty, and comorbidity burden, as these factors, not LVEF alone, are the ultimate

determinants of patient-perceived disease severity and quality of life. This highlights the

critical need for individualised, patient-centred pharmacotherapy decisions. Future

longitudinal studies are needed to establish causality and track changes in health status,

functional capacity, and comorbidity burden over time. In addition, further research with

larger, dedicated cohorts of patients with HFmrEF is required to validate our findings and

clarify the determinants of health status within this specific population. Prospective studies

should also aim to incorporate socioeconomic data, measures of medication adherence, and

social support systems to build a more comprehensive predictive model for patient-reported

outcomes in geriatric HF.

Conclusions

In this cohort of older adults with chronic heart failure, patient-reported health status was

dictated not by LVEF-based phenotype, but by the degree of functional limitation and the

weight of multimorbidity. These findings advocate for a fundamental shift in the clinical

assessment and management of geriatric HF, moving from an LVEF-centric framework to a

patient-centred approach that prioritises the evaluation and treatment of functional capacity

and comorbid conditions as the true drivers of patients' lived experiences with the disease.

Author contributions

All authors approved the final submitted version and any revised versions. Nguyen Le Huy Hoang is the guarantor with full data access and responsibility for accuracy.

Funding: None declared.

Acknowledgements

We thank the patients and their families for participating in this study. We are grateful to the clinicians, echocardiography technologists, and nursing staff at Thong Nhat Hospital for their support with patient recruitment, clinical assessments, and echocardiographic evaluations. We acknowledge the use of the Kansas City Cardiomyopathy Questionnaire (KCCQ-12), licensed from CV Outcomes, Inc. (Kansas City, Missouri, USA).

Declaration of interest: None declared.

Reference

1. Shahim B, Kapelios CJ, Savarese G, Lund LH. Global Public Health Burden of Heart Failure: An Updated Review.

2. Díez-Villanueva P, Jiménez-Méndez C, Alfonso F. Heart failure in the elderly. J Geriatr Cardiol 2021; 18 :219–32. doi: 10.11909/j.issn.1671-5411.2021.03.009.

3. Sandhu AT, Zheng J, Kalwani NM, Gupta A, Calma J, Skye M, et al. Impact of Patient-Reported Outcome Measurement in Heart Failure Clinic on Clinician Health Status Assessment and Patient Experience: A Substudy of the PRO-HF Trial. Circulation: Heart Failure 2023; 16 :e010280. doi: 10.1161/CIRCHEARTFAILURE.122.010280.

4. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure 2021; 23 :352–80. doi: 10.1002/ejhf.2115.

5. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal 2021; 42 :3599–726. doi: 10.1093/eurheartj/ehab368.

6. Vancheri F, Longo G, Henein MY. Left ventricular ejection fraction: clinical, pathophysiological, and technical limitations.

7. Garcia RA, Benton MC, Spertus JA. Patient-Reported Outcomes in Patients with Cardiomyopathy. Curr Cardiol Rep 2021; 23 :91. doi: 10.1007/s11886-021-01511-5.

8.   Spertus JA, Jones PG. Development and Validation of a Short Version of the Kansas City

Cardiomyopathy Questionnaire. Circulation: Cardiovascular Quality and Outcomes 2015;

8 :469–76. doi: 10.1161/CIRCOUTCOMES.115.001958.

9.   El-Sabawi BR, Al-Garadi MA, Steitz BD, Perkins AM, McCoy AB, Sengstack DG, et al.

Predicting Heart Failure Outcomes Using Patient-Reported Health Status. JACC 2025;

85 :2253–66. doi: 10.1016/j.jacc.2025.03.545.

10. Joseph SM, Novak E, Arnold SV, Jones PG, Khattak H, Platts AE, et al. Comparable

Performance of the Kansas City Cardiomyopathy Questionnaire in Patients With Heart

Failure With Preserved and Reduced Ejection Fraction. Circulation: Heart Failure 2013;

6 :1139–46. doi: 10.1161/CIRCHEARTFAILURE.113.000359.

11. Warraich HJ, Kitzman DW, Whellan DJ, Duncan PW, Mentz RJ, Pastva AM, et al.

Physical Function, Frailty, Cognition, Depression, and Quality of Life in Hospitalized

Adults ≥60 Years With Acute Decompensated Heart Failure With Preserved Versus

Reduced Ejection Fraction. Circulation: Heart Failure 2018; 11 :e005254. doi:

10.1161/CIRCHEARTFAILURE.118.005254.

12. Appropriate body-mass index for Asian populations and its implications for policy and

intervention strategies. The Lancet 2004; 363 :157–63. doi: 10.1016/S0140-

6736(03)15268-3.

13. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A

systematic review of definitions. BMC Geriatrics 2017; 17 :230. doi: 10.1186/s12877-

017-0621-2.

14. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A

global clinical measure of fitness and frailty in elderly people. CMAJ 2005; 173 :489–95.

doi: 10.1503/cmaj.050051.

15. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of Illness in the Aged:

The Index of ADL: A Standardized Measure of Biological and Psychosocial Function.

JAMA 1963; 185 :914–9. doi: 10.1001/jama.1963.03060120024016.

16. Lawton MP, Brody EM. Assessment of Older People: Self-Maintaining and Instrumental

Activities of Daily Living1. Gerontologist 1969; 9 :179–86. doi:

10.1093/geront/9.3_Part_1.179.

17. Mishra RK, Yang W, Roy J, Anderson AH, Bansal N, Chen J, et al. Kansas City

Cardiomyopathy Questionnaire Score Is Associated With Incident Heart Failure

Hospitalization in Patients With Chronic Kidney Disease Without Previously Diagnosed

Heart Failure. Circulation: Heart Failure 2015; 8 :702–8. doi:

10.1161/CIRCHEARTFAILURE.115.002097.

18. Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, et al. Effects of

Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure

and Reduced Ejection Fraction. Circulation 2020; 141 :90–9. doi:

10.1161/CIRCULATIONAHA.119.044138.

19. Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, et al. Empagliflozin

and health-related quality of life outcomes in patients with heart failure with reduced

ejection fraction: the EMPEROR-Reduced trial. Eur Heart J 2021; 42 :1203–12. doi:

10.1093/eurheartj/ehaa1007.

20. Butler J, Filippatos G, Jamal Siddiqi T, Brueckmann M, Böhm M, Chopra VK, et al.

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and

Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation 2022;

145 :184–93. doi: 10.1161/CIRCULATIONAHA.121.057812.

21. Butt JH, Jhund PS, Belohlávek J, de Boer RA, Chiang CE, Desai AS, et al. Efficacy and

Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A

Prespecified Analysis of the DELIVER Trial. Circulation 2022; 146 :1210–24. doi:

10.1161/CIRCULATIONAHA.122.061754.

22. Baracchini N, Capovilla TM, Costantino S, Puttini F, Salvioni E, Mattavelli I, et al. New

Fuels for a Failing Engine: The Impact of Novel Heart Failure Drugs on Functional

Capacity. RCM 2025; 26 :41919. doi: 10.31083/RCM41919.

23. Onyebeke C, Zhang D, Musse M, Unlu O, Nahid M, Ambrosy AP, et al. Polypharmacy

and Guideline-Directed Medical Therapy Initiation Among Adults Hospitalized With

Heart Failure. JACC: Advances 2024; 3 :101126. doi: 10.1016/j.jacadv.2024.101126.

24. Smith JL, Killian JM, Shippee N, Eton DT, Montori VM, Strand J, et al. Burden of

Treatment in Patients With Heart Failure. Journal of the American Heart Association

2025; 14 :e039695. doi: 10.1161/JAHA.124.039695.

Legends

Figure 1. Patient acquisition flow diagram

STROBE-style diagram illustrating the screening and enrolment process. Of 300 patients

screened, 150 were excluded for reasons including incomplete questionnaire data (n = 51),

missing left ventricular ejection fraction measurement (n = 30), acute decompensated heart

failure (n = 23), cognitive impairment (n = 23), and declined participation (n = 15), resulting

in a final cohort of 150 patients.

*Other reasons for exclusion included severe non-cardiac illness (n = 5) and planned

relocation (n = 3).

Acute decompensated heart failure (ADHF); heart failure with mildly reduced ejection

fraction (HFmrEF); heart failure with preserved ejection fraction (HFpEF); heart failure with

reduced ejection fraction (HFrEF)

Figure 2. Patient-reported health status by functional and frailty measures

Box-and-whisker plots showing the distribution of KCCQ-12 overall summary scores

stratified by (A) NYHA functional class and (B) frailty status. The boxes represent the

interquartile range (25th to 75th percentile), the horizontal line within each box indicates the

median, and the whiskers extend to the minimum and maximum values within 1.5 times the

interquartile range. The outlier (●) represents a value beyond this range.

Tables

Table 1. Baseline demographic and clinical characteristics

Characteristics	Total (n = 150)	HFrEF (n = 54)	HFmrEF (n = 23)	HFpEF (n = 73)	p-value
Age, years, median (IQR)	75 (66–84)	70 (65–80)	71 (66–82)	77 (69–85)	0.005
Age ≥75 years, n (%)	75 (50.0)	21 (38.9)	10 (43.5)	44 (60.3)	0.050
Male sex, n (%)	89 (59.3)	34 (63.0)	15 (65.2)	40 (54.8)	0.560
Current/former smoker, n (%)	51 (34.0)	19 (35.2)	9 (39.1)	23 (31.5)	0.753
Alcohol consumption, n (%)	57 (38.0)	24 (44.4)	9 (39.1)	24 (32.9)	0.409
BMI, kg/m², mean (SD)	21.6 (2.2)	21.9 (2.3)	21.4 (2.2)	21.4 (2.1)	0.450
Underweight, n (%)	16 (10.7)	4 (7.4)	2 (8.7)	10 (13.7)	
Normal range, n (%)	101 (67.3)	34 (63.0)	17 (73.9)	50 (68.5)	0.192
Overweight, n (%)	31 (20.7)	15 (27.8)	4 (17.4)	12 (16.4)	
Obese, n (%)	2 (1.3)	1 (1.9)	0 (0.0)	1 (1.4)	
LVEF, %, median (IQR)	49 (37-66)	35 (31–38)	45 (43–48)	68 (58–72)	< 0.001
Heart rate, bpm, median (IQR)	79 (65-91)	79 (65–91)	65 (63–89)	85 (68–91)	0.105

SBP, mmHg, mean (SD)	139.4 (12.0)	139.7 (12.4)	138.1 (12.6)	139.5 (11.6)	0.868
DBP, mmHg, median (IQR)	86 (78–90)	86 (81–90)	89 (76–93)	86 (78–89)	0.594
NT-proBNP, pg/mL, median (IQR)	604 (154–2,122)	573 (213–2,112)	654 (124–2,125)	623 (158–2,122)	0.814
CCI, median (IQR)	7 (5–8)	6 (5–8)	6 (5–8)	7 (5–8.5)	0.448
Polypharmacy, n (%)	132 (88.0)	50 (92.6)	23 (100.0)	59 (80.8)	0.018
Comorbidities, n (%)					
Hypertension	137 (91.3)	49 (90.7)	22 (95.7)	66 (90.4)	0.854
CAD	116 (77.3)	43 (79.6)	16 (69.6)	57 (78.1)	0.625
Atrial fibrillation	43 (28.7)	7 (13.0)	4 (17.4)	32 (43.8)	< 0.001
Diabetes mellitus	72 (48.0)	29 (53.7)	9 (39.1)	34 (46.6)	0.486
Dyslipidemia	115 (76.7)	42 (77.8)	15 (65.2)	58 (79.5)	0.356
CKD	43 (28.7)	17 (31.5)	4 (17.4)	22 (30.1)	0.473
History of stroke	9 (6.0)	3 (5.6)	1 (4.3)	5 (6.8)	1.000
Heart failure therapies, n (%)					
RAASi	96 (64.0)	37 (68.5)	18 (78.3)	41 (56.2)	0.113
Beta-blocker	65 (43.3)	28 (51.9)	13 (56.5)	24 (32.9)	0.040
MRA	91 (60.7)	48 (88.9)	17 (73.9)	26 (35.6)	< 0.001
SGLT2i	98 (65.3)	42 (77.8)	18 (78.3)	38 (52.1)	0.004

Acronyms: Body mass index (BMI); beats per minute (bpm); coronary artery disease (CAD);

Charlson Comorbidity Index (CCI); chronic kidney disease (CKD); diastolic blood pressure

(DBP); heart failure with mildly reduced ejection fraction (HFmrEF); heart failure with

preserved ejection fraction (HFpEF); heart failure with reduced ejection fraction (HFrEF);

interquartile range (IQR); left ventricular ejection fraction (LVEF); mineralocorticoid

receptor antagonist (MRA); N-terminal pro-B-type natriuretic peptide (NT-proBNP); renin-

angiotensin-aldosterone system inhibitor (RAASi); systolic blood pressure (SBP); standard

deviation (SD); sodium-glucose cotransporter-2 inhibitor (SGLT2i)

Table 2. Patient-reported outcomes and functional status by heart failure phenotype

Characteristic	Total (n = 150)	HFrEF (n = 54)	HFmrEF (n = 23)	HFpEF (n = 73)	p-value
KCCQ-12 overall summary score, median (IQR)	67.9 (57.1–81.8)	70.3 (56.3–81.3)	72.4 (59.9–83.9)	66.1 (55.7–81.3)	0.494
NYHA functional class, n (%)					0.138
I	40 (26.7)	12 (22.2)	9 (39.1)	19 (26.0)	
II	67 (44.7)	26 (48.1)	11 (47.8)	30 (41.1)	
III	39 (26.0)	15 (27.8)	3 (13.0)	21 (28.8)	
IV	4 (2.7)	1 (1.9)	0 (0.0)	3 (4.1)	
Frailty, n (%)	54 (36.0)	19 (35.2)	5 (21.7)	30 (41.1)	0.243
KCCQ-12 domain scores, median (IQR)					
Physical limitation	66.7 (41.7–83.3)	75.0 (41.7–75.0)	66.7 (50.0–83.3)	58.3 (41.7–75.0)	0.359
Symptom frequency	72.9 (64.6–85.4)	74.0 (64.6–85.4)	72.9 (70.0–93.8)	72.9 (60.4–79.2)	0.184
Quality of life	50.0 (50.0–75.0)	75.0 (50.0–75.0)	50.0 (50.0–75.0)	50.0 (50.0–75.0)	0.819
Social limitation	75.0 (66.7–83.3)	70.8 (66.7–83.3)	75.0 (66.7–91.7)	66.7 (66.7–83.3)	0.199
Functional					

independence					
ADL score, median (IQR)	6 (5–6)	6 (6–6)	6 (6–6)	6 (5–6)	0.163
ADL limitations, n (%)	38 (25.3)	12 (22.2)	3 (13.0)	23 (31.5)	0.181
IADL score, median (IQR)	8 (3–8)	8 (5–8)	8 (8–8)	8 (3–8)	0.272
IADL limitations, n (%)	54 (36.0)	19 (35.2)	5 (21.7)	30 (41.1)	0.243

Acronyms: Activities of daily living (ADL); Clinical Frailty Scale (CFS); heart failure with

mildly reduced ejection fraction (HFmrEF); heart failure with preserved ejection fraction

(HFpEF); heart failure with reduced ejection fraction (HFrEF); instrumental activities of

daily living (IADL); interquartile range (IQR); Kansas City Cardiomyopathy Questionnaire-

12 (KCCQ-12); number (n); New York Heart Association (NYHA)

Table 3. Multivariable linear regression analysis of predictors for KCCQ-12 score in the

overall cohort

Predictor	Coefficient (β)	95% CI	p-value
Age (per year)	-0.02	-0.16 to 0.12	0.753
Sex (male vs. female)	0.49	-2.64 to 3.62	0.756
HR (bpm)	-0.05	-0.12 to 0.03	0.228
CCI	-2.36	-3.03 to -1.69	< 0.001
log(NT-proBNP)	0.76	-0.81 to 2.33	0.340
Current/former smoker	3.04	-0.15 to 6.22	0.062
NYHA functional class (reference: Class I)			
Class II	-11.30	-14.45 to -8.15	< 0.001
Class III	-25.74	-29.33 to -22.16	< 0.001
Class IV	-45.28	-50.37 to -40.19	< 0.001
SGLT2i	3.89	1.30 to 6.48	0.003
Phenotype (reference: HFrEF)			
HFmrEF	-1.35	-5.01 to 2.30	0.465
HFpEF	0.86	-1.97 to 3.69	0.550
Model statistics			
R-squared	0.851		
F-statistic (12, 137)	223.39		< 0.001

Acronyms: Charlson Comorbidity Index (CCI); confidence interval (CI); heart failure with

mildly reduced ejection fraction (HFmrEF); heart failure with preserved ejection fraction

(HFpEF); heart failure with reduced ejection fraction (HFrEF); heart rate (HR); Kansas City

Cardiomyopathy Questionnaire-12 (KCCQ-12); N-terminal pro-B-type natriuretic peptide

(NT-proBNP); New York Heart Association (NYHA); sodium-glucose cotransporter-2

inhibitor   (SGLT2i)

Table 4. Multivariable linear regression analysis of predictors for KCCQ-12 score, stratified by heart failure phenotype

Predictor	HFrEF Coefficient (β)	95% CI	p-value	HFmrEF Coefficient (β)	95% CI	p-value	HFpEF Coefficient (β)	95% CI	p-value
Age (per year)	-0.02	-0.32 to 0.29	0.911	-0.16	-0.77 to 0.46	0.584	0.00	-0.20 to 0.20	0.980
Sex (male vs. female)	-1.26	-7.32 to 4.80	0.676	-7.71	-15.26 to -0.16	0.046	4.30	-1.02 to 9.62	0.112
LVEF (per 1% increase)	0.27	-0.12 to 0.66	0.174	-1.68	-2.80 to -0.55	0.007	-0.01	-0.28 to 0.27	0.939
HR (bpm)	-0.17	-0.35 to 0.01	0.067	-0.07	-0.25 to 0.10	0.392	0.02	-0.08 to 0.11	0.735
CCI	-2.36	-3.53 to -1.18	< 0.001	-3.49	-7.33 to 0.35	0.071	-2.18	-3.23 to -1.14	< 0.001
log(NT-	-0.55	-3.73 to	0.729	5.33	1.76 to 8.90	0.007	-0.88	-3.27 to	0.466

proBNP)	2.63						1.51	
Current/former smoker	4.14	-1.25 to 9.52	0.129	6.75	0.35 to 13.15	0.040	1.69	-3.65 to 7.04	0.528
NYHA functional class (reference: Class I)									
Class II	-6.01	-11.36 to -0.66	0.029	-9.49	-20.49 to 1.51	0.085	-12.69	-17.35 to -8.04	< 0.001
Class III	-22.09	-29.92 to -14.27	< 0.001	-13.89	-25.16 to -2.62	0.020	-27.43	-32.18 to -22.68	< 0.001
Class IV	-38.39	-48.61 to -28.17	< 0.001	Omitted[a]	Omitted[a]	Omitted[a]	-44.52	-52.44 to -36.60	< 0.001
SGLT2i	4.61	-1.92 to 11.14	0.162	3.38	-3.91 to 10.67	0.332	3.65	0.46 to 6.84	0.026

Model statistics						
R-squared	0.858		0.943		0.886	
F-statistic	Not reported[b]	Not reported[b]	$F(10, 12) =$ 31.37	< 0.001	$F(11, 61) =$ 205.47	< 0.001

Acronyms: Charlson Comorbidity Index (CCI); confidence interval (CI); heart failure with mildly reduced ejection fraction (HFmrEF); heart

failure with preserved ejection fraction (HFpEF); heart failure with reduced ejection fraction (HFrEF); heart rate (HR); Kansas City

Cardiomyopathy Questionnaire-12 (KCCQ-12); N-terminal pro-B-type natriuretic peptide (NT-proBNP); New York Heart Association (NYHA);

sodium-glucose cotransporter-2 inhibitor (SGLT2i)

[a]Omitted due to perfect collinearity with a small subsample.

[b]F-statistic unavailable with heteroskedasticity-robust VCE in this specification

Patients with chronic HF aged ≥60 years
screened at outpatient cardiology clinic
August 2024 – March 2025
(n = 300)

Excluded (n = 150)
• Incomplete KCCQ-12 data (n = 51)
• Missing/inadequate LVEF measurement (n = 30)
• ADHF at presentation (n = 23)
• Cognitive impairment (n = 23)
• Declined participation (n = 15)
• Other reasons* (n = 8)

Final cohort enrolled
(n = 150)

HFrEF
(n = 54)

HFmrEF
(n = 23)

HFpEF
(n = 73)